Bimekizumab 3-year Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Long-term Pooled Analysis from Five Phase 3/3b Trials. J of Skin [Internet]. 2024 Jan. 16 [cited 2026 Apr. 30];8(1):s305. Available from: https://skin.dermsquared.com/skin/article/view/2451